Mesco Pharmaceuticals Ltd has been delisted from the stock exchange.
Sector
PharmaceuticalsOpen
₹4.54Prev. Close
₹4.33Turnover(Lac.)
₹0.06Day's High
₹4.54Day's Low
₹4.5452 Week's High
₹052 Week's Low
₹0Book Value
₹-5.13Face Value
₹10Mkt Cap (₹ Cr.)
9.23P/E
0EPS
0Divi. Yield
0No Record Found
No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Equity Capital | 19.74 | 19.74 | 19.74 | 19.74 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -30.76 | -30.75 | -30.65 | -30.24 |
Net Worth | -11.02 | -11.01 | -10.91 | -10.5 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
yoy growth (%) | 0 | 0 | 0 | 0 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | 0 | 0 | -0.03 | -0.03 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 0 | -0.09 | -0.08 | -0.25 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | -0.03 | -0.01 | -0.01 | 0.01 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | 0 | 0 |
Op profit growth | -96.06 | 12.55 | -66.14 | 4,126.06 |
EBIT growth | -96.06 | 12.55 | -66.14 | -921.77 |
Net profit growth | -95.93 | 12.57 | -66.27 | -1,344.04 |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,840.55 | 147.19 | 4,41,789.55 | 608.7 | 0.87 | 4,887.27 | 93.23 |
Divis Laboratories Ltd DIVISLAB | 6,753.3 | 67.4 | 1,79,450.12 | 756 | 0.44 | 2,793 | 629.49 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,451.2 | 68.94 | 1,54,733.87 | 467 | 0 | 2,677 | 249.73 |
Cipla Ltd CIPLA | 1,417.05 | 30.86 | 1,14,182.61 | 384.64 | 0.92 | 3,840.92 | 423.38 |
Dr Reddys Laboratories Ltd DRREDDY | 1,329.35 | 34.53 | 1,11,184.65 | -219.4 | 0.6 | 3,802.6 | 375.78 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director
Dushyant Kumar Singh
Company Secretary
N S Parameshwaran
Independent Director
Hawa Singh Chahar
Director & Chief Executive Officer
Dhruv Singh
Upper Kesalton,
Tallital,
Uttar Pradesh - 263001
Tel: 91-98718 62796
Website: http://www.mescopharma.com
Email: nsparameswaran@mescosteel.com; mescogroup@rediffma
D-153/A 1st Flr,
Okhla Industrial Are, Phase-I,
New Delhi-110020
Tel: 011 - 26812682 / 83
Website: www.skylinerta.com
Email: admin@skylinerta.com
Summary
Mesco Pharmaceuticals started commercial operations in Jun.91 by venturing into seed-marketing of bulk drugs and formulations with the objective of later establishing facilities for manufacture of bul...
Read More
Reports by Mesco Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.